Energy prices remain elevated, and that keeps inflation risk on the radar for central banks and investors. When growth data looks mixed and policymakers stay cautious, many investors pay closer attention to balance sheets and cash flows. The Financially Fit Penny Stocks screener focuses on lower priced companies with healthier financial profiles. This article highlights 3 stocks from the screener that can help you research this corner of the market more confidently.

The 3 stocks covered next are just a small sample from this idea, and the full Financially Fit Penny Stocks screen surfaced 3,602 more companies with equally compelling stories that are not discussed here. To identify and analyze the setups that best fit your risk profile, head straight into the Financially Fit Penny Stocks screener.

Ardelyx (ARDX)

Overview: Ardelyx is a Waltham based biopharmaceutical company that develops and sells medicines for gastrointestinal and kidney related disorders, led by its marketed drugs IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for phosphate control in dialysis patients. These commercial products give Ardelyx a revenue generating profile that fits the Financially Fit Penny Stocks theme more closely than early stage biotechs that rely only on pipeline potential.

Operations: Ardelyx generates about US$450.9 million in revenue from the development and commercialization of its biopharmaceutical products.

Market Cap: US$1.0b

Ardelyx provides exposure to a commercial stage biotech that already earns hundreds of millions of dollars in product revenue, while still trading in penny stock territory. IBSRELA and XPHOZAH are at the center of that story, offering real world demand and a clearer line of sight to potential profitability even though the company is still reporting losses and dealing with reimbursement headwinds, especially around Medicare coverage for XPHOZAH. At the same time, reliance on a narrow product set, insider selling and a relatively new management team mean this may require close attention to upcoming milestones.

Ardelyx sits at an unusual crossroads. You get a commercial stage biotech with hundreds of millions in revenue; yet the key question is how that story holds up through reimbursement twists and concentration risk in the 4 key rewards and 1 important warning sign

Build your own financially fit penny stock shortlist

Ardelyx and the other two stocks in this article all came from a single screener, but your edge comes from setting your own ground rules. Use our flexible Screener to mix filters like revenue, balance sheet strength and risks, or jump straight into our curated Investing Ideas for ready made shortlists that match different investing styles.

Clover Health Investments (CLOV)

Overview: Clover Health Investments runs Medicare Advantage insurance plans in the United States, offering PPO and HMO coverage to Medicare-eligible individuals, and supports doctors with its Clover Assistant software that helps identify and manage chronic conditions. That tight link between a regulated Medicare book of business and a tool designed to help control medical costs is what connects Clover Health most directly to the Financially Fit Penny Stocks theme.

Operations: Clover Health generates about US$2.5b in revenue from its Insurance segment, all from the United States.

Market Cap: US$2.3b

Investors looking at Clover Health get a penny stock price tag tied to a full scale Medicare Advantage insurer with a software layer that aims to keep claims costs in check. The company’s focus on Medicare PPO and HMO plans, together with its Clover Assistant platform, ties financial health directly to how effectively it manages member outcomes and medical spending. Recent updates show growing membership, positive GAAP net income and higher full year revenue and EBITDA guidance, yet the stock still carries funding risk, a history of losses and insider selling that call for a closer look. For investors willing to weigh those trade offs, Clover Health offers a complex mix of insurance cash flows, technology potential and regulatory exposure that warrants deeper research.

Clover Health’s mix of Medicare scale, software ambitions and fresh profitability headlines raises an obvious question: What is the real story behind those cash flows and risks in the analysis report for Clover Health Investments

Hyliion Holdings (HYLN)

Overview: Hyliion Holdings develops the KARNO Power Module, a fuel agnostic generator that provides distributed power for stationary and mobile uses using everything from natural gas and diesel to landfill gas, renewable hydrogen and ammonia. For investors, Hyliion offers penny stock exposure to cleaner on site power solutions that aim to serve data centers, industrial sites and defense applications without tying the story only to one type of fuel or end market.

Operations: Hyliion currently generates about US$9.2 million in revenue, all from Auto Parts & Accessories in the United States.

Market Cap: US$725.1 million

Hyliion Holdings draws interest in this Financially Fit Penny Stocks theme because the KARNO Power Module targets demand for reliable on site power and lower emissions while still trading in penny stock territory. The company has early revenue, a US$41.7 million U.S. Navy contract, non binding interest for hundreds of KARNO cores and raised 2026 revenue guidance to about US$15 million. At the same time, it remains pre commercial, with research and development services as the main revenue source and ongoing losses that could require further funding. If you are looking for cleaner energy exposure with a stronger balance sheet focus than many early stage peers, Hyliion offers a mix of contracts, governance experience and commercialization risk that may warrant closer research.

Hyliion’s contract wins and wider fuel options hint at a bigger story that many investors may be glossing over. Step into the analyst forecasts for Hyliion Holdings to see how the balance between early revenue and future scale really looks before one detail changes the whole picture

Seeking Alternatives Before Everyone Else?

Fresh stock ideas can move quickly. Some gain breakout momentum, while others drop off the radar. Scan what is still under the radar for now and consider acting before attention increases.

• Spot established cash generators that still appear overlooked by the market, then size up a hand picked set of under the radar companies using the 19 high quality undiscovered gems.
• Track where capital and attention are already moving toward infrastructure behind AI, and pressure test that momentum against a curated basket through the 56 AI infrastructure stocks.
• Build your watchlist around cash flow strength and balance sheet resilience by scanning the list of solid balance sheet and fundamentals (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.